CL2017000438A1 - Sistema de señalización - Google Patents

Sistema de señalización

Info

Publication number
CL2017000438A1
CL2017000438A1 CL2017000438A CL2017000438A CL2017000438A1 CL 2017000438 A1 CL2017000438 A1 CL 2017000438A1 CL 2017000438 A CL2017000438 A CL 2017000438A CL 2017000438 A CL2017000438 A CL 2017000438A CL 2017000438 A1 CL2017000438 A1 CL 2017000438A1
Authority
CL
Chile
Prior art keywords
domain
union
signaling
component
agent
Prior art date
Application number
CL2017000438A
Other languages
English (en)
Spanish (es)
Inventor
Martin Pulé
Khai Kong
Shaun Cordoba
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of CL2017000438A1 publication Critical patent/CL2017000438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2017000438A 2014-08-29 2017-02-23 Sistema de señalización CL2017000438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1415347.2A GB201415347D0 (en) 2014-08-29 2014-08-29 Signalling system

Publications (1)

Publication Number Publication Date
CL2017000438A1 true CL2017000438A1 (es) 2017-08-18

Family

ID=51752358

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000438A CL2017000438A1 (es) 2014-08-29 2017-02-23 Sistema de señalización

Country Status (18)

Country Link
US (2) US10654927B2 (2)
EP (2) EP3981417A1 (2)
JP (1) JP6614619B2 (2)
KR (1) KR102222615B1 (2)
CN (1) CN106573989B (2)
AU (1) AU2015308243B2 (2)
BR (1) BR112017003906A2 (2)
CA (1) CA2955668A1 (2)
CL (1) CL2017000438A1 (2)
ES (1) ES2910008T3 (2)
GB (1) GB201415347D0 (2)
IL (1) IL250101B (2)
MX (1) MX376613B (2)
NZ (1) NZ728674A (2)
RU (1) RU2731638C2 (2)
SG (1) SG11201700171VA (2)
WO (1) WO2016030691A1 (2)
ZA (1) ZA201700466B (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11879016B2 (en) 2014-03-06 2024-01-23 Autolus Limited Chimeric antigen receptor
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
EP3288570A4 (en) * 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
GB201602571D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602563D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
EP3472318B1 (en) * 2016-07-08 2023-09-06 Exuma Biotech Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP2019535262A (ja) 2016-11-11 2019-12-12 オートラス リミテッド キメラ抗原受容体
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
GB201621891D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Transcription system
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
JP7132249B2 (ja) * 2017-05-15 2022-09-06 オートラス リミテッド キメラ抗原受容体（ｃａｒ）を含む細胞
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
GB201709508D0 (en) * 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
CN107475276A (zh) * 2017-09-05 2017-12-15 深圳大学 嵌合抗原受体及其表达基因、四环素调节的嵌合抗原受体修饰的t细胞及其应用
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
GB201805918D0 (en) * 2018-04-10 2018-05-23 Autolus Ltd Cell
WO2019197676A1 (en) 2018-04-13 2019-10-17 Ludwig Institute For Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
GB201807693D0 (en) 2018-05-11 2018-06-27 Autolus Ltd Cell
AU2019269118B2 (en) 2018-05-15 2025-02-27 Autolus Limited Chimeric antigen receptor
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
EP3847197A1 (en) * 2018-09-05 2021-07-14 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
PL3856775T3 (pl) 2018-09-27 2025-06-09 Autolus Limited Chimeryczny receptor antygenowy
GB201816839D0 (en) * 2018-10-16 2018-11-28 Glaxosmithkline Ip Dev Ltd Novel control switch
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
GB201906202D0 (en) 2019-05-02 2019-06-19 Autolus Ltd Cell
US20220257757A1 (en) 2019-07-16 2022-08-18 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
GB201913258D0 (en) 2019-09-13 2019-10-30 Autolus Ltd Antigen-binding domain
GB201919017D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Cell
GB201919019D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
WO2021205175A1 (en) 2020-04-09 2021-10-14 Autolus Limited Molecule
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
GB202017343D0 (en) 2020-11-02 2020-12-16 Autolus Ltd Cell
GB202104030D0 (en) 2021-03-23 2021-05-05 Autolus Ltd Signalling system
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
GB202219568D0 (en) 2022-12-22 2023-02-08 Autolus Ltd Chimeric antigen receptor
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
EP4303232A3 (en) * 2013-02-15 2024-04-17 The Regents of The University of California Chimeric antigen receptor and methods of use thereof
PL3546572T3 (pl) 2013-05-13 2024-07-22 Cellectis Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
US20160296562A1 (en) * 2013-11-21 2016-10-13 Ucl Business Plc Cell
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
US9791929B2 (en) * 2014-10-31 2017-10-17 Elwha Llc Tactile control system
KR102376244B1 (ko) * 2014-12-24 2022-03-21 오토러스 리미티드 세포
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
WO2017123559A2 (en) * 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
GB201602571D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602563D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201610515D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Cell

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11885806B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11879016B2 (en) 2014-03-06 2024-01-23 Autolus Limited Chimeric antigen receptor
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells

Also Published As

Publication number Publication date
WO2016030691A1 (en) 2016-03-03
AU2015308243A1 (en) 2017-02-23
BR112017003906A2 (pt) 2018-02-27
IL250101A0 (en) 2017-03-30
JP2017526361A (ja) 2017-09-14
ES2910008T3 (es) 2022-05-11
RU2731638C2 (ru) 2020-09-07
EP3981417A1 (en) 2022-04-13
RU2017105515A3 (2) 2018-10-01
US20210032332A1 (en) 2021-02-04
US20170260269A1 (en) 2017-09-14
KR102222615B1 (ko) 2021-03-05
SG11201700171VA (en) 2017-02-27
EP3185875B1 (en) 2022-01-05
RU2017105515A (ru) 2018-10-01
CN106573989B (zh) 2022-02-01
GB201415347D0 (en) 2014-10-15
EP3185875A1 (en) 2017-07-05
CA2955668A1 (en) 2016-03-03
NZ728674A (en) 2020-05-29
MX376613B (es) 2025-03-07
US10654927B2 (en) 2020-05-19
AU2015308243B2 (en) 2020-01-30
KR20170045258A (ko) 2017-04-26
ZA201700466B (en) 2018-08-29
CN106573989A (zh) 2017-04-19
MX2017000616A (es) 2017-07-20
IL250101B (en) 2020-11-30
JP6614619B2 (ja) 2019-12-04

Similar Documents

Publication Publication Date Title
CL2017000438A1 (es) Sistema de señalización
CL2017001314A1 (es) Célula
CL2017002413A1 (es) Receptor antigénico quimérico
CO2019000946A2 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
MX2018008352A (es) Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b.
MX2018005674A (es) Receptores de antigenos quimericos dirigidos a her2.
CR20190050A (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
CO2017006808A2 (es) Receptores de antígenos quiméricos de bcma
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
PE20170125A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
EA201591740A1 (ru) Вирусы болезни ньюкасла и их применение
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
MX2018006875A (es) Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab.
PE20161344A1 (es) Determinantes de respuesta del cancer a la inmunoterapia
CL2017000250A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
CL2017000110A1 (es) Moléculas con especificidad para dc79 y cd22
TR201903074T4 (tr) Prostat ile bağlantılı antijenlerin ekspresyonuna yönelik vektörler.
MX2016016771A (es) Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso.
BR112015020516A2 (pt) composições e métodos para imunoterapia
MX2015013104A (es) Composiciones y métodos para la inmunoterapia.
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
CL2017000360A1 (es) Nuevos anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon